Cardurion is a cardiovascular biotechnology company developing therapeutics for the treatment of heart failure and cardi
Cardurion is a cardiovascular biotechnology company developing therapeutics for the treatment of heart failure and cardiovascular diseases.
Biotechnology📍 Burlington, MAFounded 2017
Current Valuation
$760M
as of 2024-Q3
PRIVATE
QL Price
$760M
0% vs last round
QuantLogix's current estimate for Cardurion Pharmaceuticals, published 2026-09-27 — in line with the last disclosed round of $760M (2024-Q3).
Confidence
low
Basis
round anchored
What backs this price
Last disclosed round
$760M
2024-Q3
weight 0.25
How this price has held up
No round has priced for Cardurion Pharmaceuticals since QuantLogix began publishing a price for it, so there is nothing to grade yet. The claim above is on the record from 2026-09-27 and will be graded against the next priced round. See the full accuracy record →
Which publicly-traded funds already hold it, what $10,000 buys, and whether any route is open to you.
Cite this price as QuantLogix QL Price, Cardurion Pharmaceuticals, 2026-09-27 (cb0c0c03a262b8a9).
The id pins this exact claim, so a citation stays checkable after the price moves.
Model estimate for research — not a quote, target price, or investment advice.
IPO Outlookprivate
Is Cardurion Pharmaceuticals going public?
No. Cardurion Pharmaceuticals is private and has not filed to go public. There is no S-1 on file.
What is Cardurion Pharmaceuticals' valuation in 2026?
Cardurion Pharmaceuticals is valued at $760M as of 2024-Q3, set by its Series B ($260M, Jul 2024). That is the last confirmed mark, not a live price — private shares do not trade continuously.
Has Cardurion Pharmaceuticals filed an S-1?
No public S-1 is on file for Cardurion Pharmaceuticals.
How much has Cardurion Pharmaceuticals raised?
Cardurion Pharmaceuticals has raised $603.15M in total, most recently a Series B of $260M in Jul 2024.
Is Cardurion Pharmaceuticals publicly traded — can you buy Cardurion Pharmaceuticals stock?
No. Cardurion Pharmaceuticals is a private company — its shares are not listed on any exchange and there is no ticker. The routes to exposure are pre-IPO secondary marketplaces and funds (accredited investors), employee tender offers when the company runs one, and public companies with read-through exposure. QuantLogix maps every route it can verify for Cardurion Pharmaceuticals on its Pre-IPO Access Desk.
Answers are derived from the roster record shown on this page — filing status, last round and confirmed marks. Where the record is silent, the answer says so rather than guessing.
Company Profile
Founded
2017
HQ
Burlington, MA
Employees
50
Total Raised
$603.15M
Last Round
Series B — $260M (Jul 2024)
IPO Status
private
Fundraising Status
Series B · $260M · 2y 2mo ago
privateTotal raised $603.15M
Latest Funding Round
Round
Amount
Date
Lead Investor
Post-Money
Series B
$260M
Jul 2024
—
$760M
Vertical Intelligence — Biotech / Gene Therapy
Registered trials
12
2 active · 2 recruiting
Lead phase
Phase 2
most advanced registered study
Focus areas
Heart Failure
Cardiovascular Diseases · Heart Diseases
Latest trial start
2026-07-15
Name-verified against lead sponsor "Cardurion Pharmaceuticals, Inc." on ClinicalTrials.gov as of 2026-09-19. Verify on ClinicalTrials.gov ↗
Talent Signal
No public careers page or job board could be found for Cardurion Pharmaceuticals as of 2026-09-16. That itself is a datapoint: no open external hiring surface.
Checked the company site and major hosted job boards. Re-checked monthly.
BiotechnologyHealth CareMedicalPharmaceutical
Private-company numbers are not real-time. Reflects publicly disclosed valuations from press releases, news reports, and tender offers as of 2024-Q3. Refreshed quarterly.